Standardized Assays for Personalized Immune Response MonitoringThis online seminar will provide an overview of recent research published in the journal Immunity that demonstrates progress in the standardization of assays for personalized immune response monitoring.
Thursday, May 15, 2014 12:00 pm (Eastern Standard Time)
Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue using Myriad RBM’s Multiplex ApoptosisMAP™Learn about the creation of Myriad RBM’s fully validated, quantitative ApoptosisMAP and its application in cancer therapy research. The webinar highlights the main features of the service, including the ability to measure key heterodimers in the apoptosis pathway, and describes its utility for identifying responders to apoptosis inducers or other chemotherapeutic regimes.
SMA-MAP: A multiplexed immunoassay biomarker panel for Spinal Muscular AtrophyLearn about an approach used for developing biomarkers in rare, pediatric disease and gain insights on current and future utility of the SMA-MAP panel in SMA and other neuromuscular research.
Translating Preclinical Pharmacology in Clinical ActivityWatch to learn how Myriad RBM’s products and services were used by VentiRx to compare potency, define PK/PD relationships, identify potential clinical biomarkers of VTX-2337 activity and establish a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial.
Drug Induced Kidney Injury Biomarkers: Data From Four SpeciesTranslatability and Utility in Drug Safety Studies and Kidney Disease Research – Find out how this suite of solutions, developed in conjunction with the Predictive Safety Testing Consortium (PSTC), can help you expedite translational development from pre-clinical animal studies to early clinical testing.
How to Implement a Sound Biomarker Strategy to Increase Your Success Rate in Drug Development.Learn how Myriad RBM’s Strategic Biomarker Services can save time and money or even resurrect a late-stage failure.
Recorded webinar coming soon.